To study the efficacy and safety of combination treatment using allopurinol and fenofibrate in patients with hyperuricemia
Journal Title: Pakistan Journal of Pharmacology - Year 2012, Vol 29, Issue 1
Abstract
Allopurinol is the most frequently used antihyperuricemic drug. Fenofibrate, a derivative of fibric acid, is commonly used in the treatment of hyperlipidemia. Fenofibrate treatment has been shown to decrease serum urate levels. This study was conducted to compare the efficacy and safety of combination treatment using allopurinol 100mg and fenofibrate 67mg daily with allopurinol 300mg daily. Sixty hyperuricemic patients with serum uric acid level 7.0mg per deciliter or above were enrolled and assigned to take either allopurinol 300mg or combination treatment using allopurinol 100mg + fenofibrate 67mg daily for 12 weeks. Drug efficacy was assessed by measuring percentage of subjects achieving serum uric acid level less than 6mg per deciliter at day 90. Drug efficacy was also assessed by measuring percent change in serum uric acid level from day 0 to day 90. Safety of the drug was assessed by reviewing adverse effects (AEs) and laboratory values. Comparison of percentage of subjects reaching serum uric acid level less than 6.0mg per deciliter at day 90 between the two groups was highly significant (P=0.001). Similarly percent change in serum uric acid level from day 0 to day 90 was also highly significant between the two groups (P=0.001). Our results showed that allopurinol 300mg once daily is more effective than combination treatment using allopurinol 100mg plus fenofibrate 67mg. However proportions of subjects experiencing any adverse event were higher in allopurinol 300mg group. Similarly the adverse effects leading to treatment withdrawal were higher in allopurinol group. Allopurinol 300mg once daily is more effective antihyperuricemic agent than combination treatment using allopurinol 100mg plus fenofibrate 67mg.
Authors and Affiliations
Irfan Zafar, Moosa Khan, Abdul Junejo, Syeda Zain
Keywords
Related Articles
- EP ID EP114757
- DOI -
- Views 111
- Downloads 0
Alendronate a promising / multi aspect drug in the management of ostoeoporosis
Recently, osteoporosis is regarded as a major health concern due to increase in its incidence, associated morbidities and mortalities. Among antiresorptives, alendronate which is a bisphosphonate is FDA (Food and Drug Ad...
Interferon (IFN a) induced depression in patients of hepatitis C (HCV)
HCV is a global problem and the worst affected are the 3rd world countries. In our study of 802 patients 244 male and 161 females were positive for HCV. Majority of the patients were in age group 26-40 Years i-e 56.04% o...
Comparative study of succinylcholine and precurarization with rocuronium on muscular effects in patients undergoing surgery under general anaesthesia
Succinylcholine remains the drug of choice in conditions where rapid paralysis and airway control are priorities. However it is associated with muscular side effects that have an overall incidence ranging from five to 83...
Frequency of anemia and its association with outcome (sustained virological response) in patients of chronic hepatitis C Geno 3, treated with standard interferon alpha 2a and ribavirin
Chronic Hepatitis C is one of the leading cause of chronic liver disease globally. The past two decades have seen many advances in Hepatitis C treatment. Despite these advances side effects of treatment are common. Hemat...
Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: A qualitative review
Obsessive-compulsive disorder (OCD) is a relatively common disorder, most of the time under diagnosed and under treated despite the existence of effective treatments. OCD can be discriminated from other disorders, having...